California’s Life Sciences Sector Applauds Gov. Brown on New Public-Private Precision Medicine Initiative

April 14, 2015

California’s Life Sciences Sector Applauds Gov. Brown on New Public-Private Precision Medicine Initiative

California Initiative to Advance Precision Medicine will focus on data sharing between UC System and industry to advance precision therapies

San Diego, Calif. – April 14, 2015 – Sara Radcliffe, president & CEO of the California Healthcare Institute (CHI), issued the following statement today regarding the unveiling of Gov. Jerry Brown’s California precision medicine collaboration initiative:

“CHI commends Governor Brown for his leadership on this bold new initiative that will help unleash the power of public-private partnerships to further develop the field of precision medicine in California. This far reaching collaboration between the University of California and other stakeholder partners throughout the state will focus on collecting and utilizing data in clinical, genomic, socioeconomic, mobile, environmental and other areas, to help drive the development of precision medicine-based tools, treatments and technologies.

Many of our CHI member companies, universities and research institutes are already working in the precision medicine space. The California Initiative to Advance Precision Medicine will help accumulate, combine, leverage current and forthcoming data from across the state’s leading universities and research institutes for collaborative advancements with private-sector partners.

As the birthplace of biotechnology, California holds a unique position to lead and advance the promise of precision medicine for the rest of the world. On behalf of California’s life sciences sector, we applaud Governor Brown and UC President Janet Napolitano for their thoughtful and visionary support to advance precision medicine research here in California.”

View press release on BusinessWire.

About Precision Medicine:
Precision medicine research is a relatively new area of biomedical research that targets an individual’s molecular biology to better understand and combat disease. Advances in precision medicine, including tools to facilitate the analysis of large and complex datasets, will help provide better understanding about the causes of different diseases, determine who is most at risk, and guide the development of technologies to prevent, diagnose, treat and cure conditions at the individual patient level. Learn more at the National Institutes of Health (NIH).

About CHI-California Healthcare Institute
CHI represents more than 275 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance biomedical research, investment and innovation through effective advocacy of policies to improve public health and ensure continued vitality of the life sciences sector. CHI’s website is Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Will Zasadny
Manager – Communications